Streetbeat News

XPH

SPDR S&P Pharmaceuticals ETF

https://www.ssga.com/us/en/intermediary/etfs/funds/spdr-sp-pharmaceuticals-etf-xph?fundSeoName=spdr-sp-pharmaceuticals-etf-XPH

Industry

Asset Management

In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

The Supreme Court has rejected Purdue Pharma's bankruptcy plan, which would have shielded the Sackler family from civil lawsuits related to the opioid crisis. This decision allows ongoing lawsuits against the Sacklers and impacts the distribution of funds for opioid abatement.

Portfolio Pulse from Vandana Singh

June 27, 2024 | 4:31 pm

Organon & Co (NYSE:OGN) reported a first-quarter revenue of $1.622 billion, a 5% increase year-over-year, surpassing the consensus of $1.563 billion. The growth was led by an 11% increase in Women's Health revenue, notably from Nexplanon, and a 46% surge in Biosimilar revenue, driven by Ontruzant and Renflexis. Despite a flat performance in Established Brands, the company beat adjusted EPS estimates with $1.22 against a consensus of $0.93. However, adjusted gross margin and EBITDA margin saw slight declines. Organon declared a quarterly dividend of $0.28 per share and reaffirmed its FY24 revenue guidance of $6.2 billion to $6.5 billion. OGN shares rose 2.18% to $19.24. Exposure to Organon's stock can also be gained through SPDR S&P Pharmaceuticals ETF (NYSE:XPH) and Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH).

Portfolio Pulse from Lekha Gupta

May 02, 2024 | 5:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.